Multiyear alliance underpins Randox commitment to increase biochip manufacturing to transform rapid diagnostic testing
- Multiyear alliance underpins Randox commitment to increase biochip manufacturing to transform rapid diagnostic testing
- SCIENION to integrate its precision dispensing technology to enable Randox to scale-up Biochip manufacturing across the business
- Joint activities will include co-working at Randox, Crumlin (Northern Ireland), Randox, Dungloe (Republic of Ireland), and at SCIENION headquarters in Berlin (Germany) – including massive scaling-up of SARS CoV2 test manufacturing
Randox announced an important step in scaling-up biochip manufacturing by selecting SCIENION as its technology provider and science partner for this effort. The SCIENION engineering team has developed another full custom-made solution of the S100 in-line system to fulfill Randox’s manufacturing needs. SCIENION S100 manufacturing technology will significantly bolster Randox capabilities from research through commercialization and help accelerate the discovery and development of transformative diagnostics for patients worldwide.
Building on the well-established partnership between both companies, Randox and SCIENION have committed to immediately employ the new technology at manufacturing sites. This strategic alliance will focus on one core objective: to increase Randox manufacturing capacity for biochips significantly and immediately.
SCIENION and Randox will also collaborate to develop and apply next-generation diagnostics platforms and processes that support future key programs. The overall investment will include project funding, subject-matter experts, technology, and tools.
Mr John Lamont – Director of R&D at Randox Laboratories, said, “As Randox continues evolving into a focused diagnostics company powered by advanced multiplexed tests and data science, alliances like this will help us deliver on our goal to improve healthcare worldwide. Pairing our deep understanding of diagnostics with SCIENION’s expertise in high throughput microarray manufacturing, this could transform the way we discover and develop diagnostic tests for the world.”
SCIENION UK Managing Director, Dr. Andrew Sweet, added, “Our strategic alliance will combine Randox Diagnostics expertise with the power of SCIENION precision liquid handling and sciFLEXARRAYER S100 technology. Together, we aim to address some of the biggest challenges facing the life sciences industry. This would quickly bring reliable rapid diagnostic testing technology to the frontline for widespread use in all affected regions during a pandemic such as SARS-CoV2.
Related Reports and Monitors
BioMEMS Market and Technology 2020
Market & Technology
Thinning Equipment Technology and Market Trends for Semiconductor Devices
Market & Technology